Sign in

Private company

PLx Pharma Winddown Corp.

American pharmaceutical preparations company, incorporated in Delaware1

In its 2022 annual report the company says: “The Company, together with its subsidiary PLx Opco Inc., is a commercial-stage drug delivery platform technology company focused on improving how and where active pharmaceutical ingredients are absorbed in the gastrointestinal GI tract via its clinically-validated and patent-protected PLxGuard™ technology. The Company has two Food and Drug Administration approved products, VAZALORE® 81 mg and VAZALORE® 325 mg, which are liquid-filled aspirin capsules for over-the-counter distribution.”54 It is headquartered in Sparta, New Jersey.1

Last updated Oct 21, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersSparta, New Jersey1
  • Incorporated inDE2
  • Business address9 Fishers Lane, Suite E, Sparta, Nj 078712
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2021

41.5%Gross margin3
-497.0%Operating margin3
-562.0%Net margin3
27260.0%Revenue growth, 20213
-129.3%Return on equity3

Where the money goes

Where each dollar of revenue went, fiscal 2021

  • Cost of revenue10¢$4.8M
  • Research and development9¢$4.2M
  • Selling, general and admin82¢$40.0M

Out of $8.2M in revenue.3 The company lost money this year.

Financial statements

Revenue45673$8.2M in 2021
0$2.5M$5.0M$7.5M$10.0M2015: $0$020152016: $20.0K$20.0K20162017: $778.7K$778.7K2017+3793%2018: $753.1K$753.1K2018−3%2019: $565.5K$565.5K2019−25%2020: $30.0K$30.0K2020−95%2021: $8.2M$8.2M2021+27260%
Gross profit3$3.4M in 2021+11243% since 2020
0$1.0M$2.0M$3.0M$4.0M2020: $30.0K$30.0K20202021: $3.4M$3.4M2021+11243%
Operating income456873-$40.8M in 2021+117% since 2015
-$60.0M-$40.0M-$20.0M02015: -$18.8M-$18.8M20152016: -$4.8M-$4.8M2016−74%2017: -$15.8M-$15.8M2017+229%2018: -$11.0M-$11.0M2018−31%2019: -$14.2M-$14.2M2019+30%2020: -$13.5M-$13.5M2020−5%2021: -$40.8M-$40.8M2021+203%
Net income456873-$46.1M in 2021+146% since 2015
-$60.0M-$40.0M-$20.0M0$20.0M2015: -$18.7M-$18.7M20152016: -$4.9M-$4.9M2016−74%2017: -$15.3M-$15.3M2017+213%2018: $896.5K$896.5K20182019: -$20.5M-$20.5M20192020: -$15.2M-$15.2M2020−26%2021: -$46.1M-$46.1M2021+203%
Fiscal year2015201620172018201920202021
Revenue$04$20.0K5$778.7K6$753.1K6$565.5K7$30.0K3$8.2M3
Cost of revenue$03$4.8M3
Gross profit$30.0K3$3.4M3
Research and development$78.7K5$4.2M6$3.9M8$4.7M7$4.3M3$4.2M3
Selling, general and admin$9.2M3$40.0M3
Operating expenses$44.2M3
Operating income-$18.8M4-$4.8M5-$15.8M6-$11.0M8-$14.2M7-$13.5M3-$40.8M3
Income before tax-$46.1M3
Income tax$011-$920.0K6$03$03
Net income-$18.7M4-$4.9M5-$15.3M6$896.5K8-$20.5M7-$15.2M3-$46.1M3
Earnings per share-$2.196$0.108-$3.847-$1.747
Earnings per share (diluted)-$2.196$0.108$8,916,190.007$9,714,951.007

Compare PLx Pharma Winddown Corp. with another company

Corporate structure

PLx Pharma Winddown Corp. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of PLx Pharma Winddown Corp.

  • PLx Pharma Winddown Corp. Sparta, New Jersey

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What PLx Pharma Winddown Corp. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$1.3M3 Dec 31, 2021$1.7M3 Dec 31, 2020−21.0%
Accumulated depreciation$465.0K3 Dec 31, 2021$448.0K3 Dec 31, 2020+3.8%
Property and equipment, net$858.0K3 Dec 31, 2021$1.2M3 Dec 31, 2020−30.0%
Operating-lease assets (leased space)$230.0K3 Dec 31, 2021$327.0K3 Dec 31, 2020−29.7%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$69.4M3 Dec 31, 2021$22.4M3 Dec 31, 2020+209.1%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$2.1M3 Dec 31, 2021$2.1M3 Dec 31, 20200%

Inventory

ItemLatestA year beforeChange
Inventory, total$2.5M3 Dec 31, 2021$143.0K3 Dec 31, 2020+1618.9%
Raw materials$132.0K3 Dec 31, 2021$143.0K3 Dec 31, 2020−7.7%
Work in process$338.0K3 Dec 31, 2021$03 Dec 31, 2020
Finished goods$2.0M3 Dec 31, 2021$03 Dec 31, 2020

Leadership

Who has led PLx Pharma Winddown Corp., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. David P. Luci2014–2016
  2. Natasha Giordano2017–2022

Chair

  1. Robert J. Deluccia2014–2017
  2. Michael J. Valentino2017–2022

President

  1. David P. Luci2014–2016
  2. Natasha Giordano2017

Chief financial officer

  1. David Emerson Jorden2017
  2. Rita M. O'Connor2017–2022

Chief operating officer

  1. Gary L. Mossman2017
201520202025
Board members and other officers (14)

Former names

  • PLx Pharma Inc.Feb 21, 2017 to May 2, 20232
  • Dipexium Pharmaceuticals, Inc.Jan 21, 2014 to Apr 20, 20172
  • Dipexium Pharmaceuticals, LLCJul 30, 2010 to Mar 13, 20142

Timeline

  1. Sep 20, 20238-K Bankruptcy or receivership; Other events31
  2. Aug 22, 20238-K Other events32
  3. Jul 21, 20238-K Other events33
  4. Jul 12, 20238-K Other events34
  5. Jul 7, 20238-K Executive or director change; Bylaws or fiscal year changed35
  6. Jun 27, 20238-K Other events36
  7. May 26, 20238-K Entered a material agreement; Bankruptcy or receivership; Completed an acquisition or sale37
  8. Apr 13, 20238-K Bankruptcy or receivership38
  9. Apr 12, 20238-K Entered a material agreement; Other events39
  10. Apr 10, 20238-K Listing notice or transfer40
  11. Mar 8, 20238-K Executive or director change; Other events41
  12. Feb 13, 20238-K Listing notice or transfer; Executive or director change42
  13. Apr 20, 2017New chief executive Natasha Giordano becomes CEO12
  14. Mar 12, 2014New chief executive David P. Luci becomes CEO13

Calendar

When it reported results

  1. Nov 10, 2022Reported quarterly or annual results43
  2. Aug 12, 2022Reported quarterly or annual results44
  3. May 13, 2022Reported quarterly or annual results45
  4. Mar 11, 2022Reported quarterly or annual results46
  5. Nov 12, 2021Reported quarterly or annual results47

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

46 filings to the SEC since October 2021: 2 annual reports, 4 quarterly reports, 21 major events, 9 insider forms, 5 large holders, 5 other. The latest 20:

  1. Oct 18, 202315-12G EDGAR
  2. Sep 20, 20238-K EDGAR
  3. Aug 22, 20238-K EDGAR
  4. Jul 21, 20238-K EDGAR
  5. Jul 12, 20238-K EDGAR
  6. Jul 7, 20238-K EDGAR
  7. Jun 27, 20238-K EDGAR
  8. May 26, 20238-K EDGAR
  9. Apr 13, 20238-K EDGAR
  10. Apr 12, 20238-K EDGAR
  11. Apr 10, 20238-K EDGAR
  12. Apr 6, 2023SC 13G EDGAR
  13. Mar 8, 20238-K EDGAR
  14. Feb 14, 2023SC 13G/A EDGAR
  15. Feb 13, 20238-K EDGAR
  16. Jan 20, 20238-K EDGAR
  17. Nov 10, 202210-Q EDGAR
  18. Nov 10, 20228-K EDGAR
  19. Oct 7, 20228-K EDGAR
  20. Sep 29, 2022DEFA14A EDGAR

The 46 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

2 open-market trades by officers, directors and large owners since October 2021: 2 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Mar 15, 2022Giordano NatashaChief Executive OfficerBuy4,100$3.65$15.0KForm 4
Mar 15, 2022O'Connor Rita MChief Financial OfficerBuy13,700$3.66$50.1KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How PLx Pharma Winddown Corp. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARPLx Pharma Winddown Corp.1
  • CIK0001497504
  • Employer ID (EIN)27-17079621
  • Filer statusNon-accelerated filer<br>smaller reporting company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • Business address9 Fishers Lane, Suite E, Sparta, NJ 078711
  • Phone(713) 842-12491
  • Shares outstanding29,137,692 as of Nov 8, 202210
  • Public float$335.7M as of Jun 30, 202153
  • On EDGAR sinceJul 30, 20101
  • Filings369 in all: 4 (92), 8-K (88), 10-Q (27), 3 (24), CORRESP (16), UPLOAD (13), SC 13G/A (11), DEF 14A (9)1
    All 38 form types

    SC 13G (9), 10-K (8), D (8), EFFECT (8), S-3 (6), 10-K/A (5), 424B5 (5), SC 13D/A (4), 424B3 (3), CT ORDER (3), DEFA14A (3), PRE 14A (3), S-8 (3), 424B4 (2), 425 (2), S-1/A (2), SC 13D (2), 15-12G (1), 25-NSE (1), 3/A (1), 8-A12B (1), 8-K/A (1), CERTNAS (1), D/A (1), DEL AM (1), DRS (1), S-1 (1), S-1MEF (1), S-4 (1), S-4/A (1)

  • Latest filingsAnnual report (10-K) Mar 11, 2022
    Quarterly report (10-Q) Nov 10, 2022
    Proxy statement (DEF 14A) Sep 29, 2022
    Latest 8-K (8-K) Sep 20, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
    SEC EDGAROther events
  33. 33
    SEC EDGAROther events
  34. 34
    SEC EDGAROther events
  35. 35
  36. 36
    SEC EDGAROther events
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54